Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Abstract

Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line treatment in <i>EGFR</i>-mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.).